Skip to main content
Clinical Trials/NCT00000519
NCT00000519CompletedPhase 3

Exercise Training and Plasma Lipoproteins in Man

Stanford University0 sitesStarted: October 28, 1999Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed

Study Overview

Brief Summary

To determine the effects in moderately obese subjects of weight loss by combined dieting and exercise training on risk factors for coronary artery disease including lipoprotein lipids, apoproteins and blood pressure.

Detailed Description

BACKGROUND:

Evidence appears to be fairly conclusive that obesity has adverse effects on health and longevity when the relative body weight is 40 percent above desirable weight based on insurance industry tables of weights. The close association between obesity, hypertension, hypercholesterolemia, non-insulin dependent diabetes mellitus, an excess of certain cancers and other medical problems makes it imperative that interventions be directed to change the lifestyles and behaviors of individuals who are overweight. The Stanford Weight Control Project (SWCP) trial examined the effects of weight loss on cardiovascular disease risk factors.

The Stanford Weight Control Project (SWCP) randomized 155 overweight, sedentary, non-smoking men, aged 30-59 years, to one of three groups. Fifty-one were assigned to weight loss through dieting, 52 to weight loss through exercise, and 52 to a control, non-intervention group. Follow-up continued through July 1989.

DESIGN NARRATIVE:

Subjects were randomized to a control group, a hypocaloric National Cholesterol Education Program (NCEP) diet, or to a hypocaloric NCEP diet with exercise. One hundred nineteen of the men and 112 of the women returned for testing after one year.

Study Design

Study Type
Interventional
Allocation
Randomized
Primary Purpose
Prevention

Eligibility Criteria

Ages
25 Years to 49 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Men and women, ages 25-
  • •Subjects were overweight with blood pressure less than 160/95 mm Hg and total cholesterol less than 260 mm/dl.

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Exercise Training and Plasma Lipoproteins... | Clinical Trial